- Home
- Clinical Trials
Bronchiectasis Study Wellington 13
Bronchiectasis Study
Wellington
Do you suffer from Bronchiectasis – a lung condition that can make breathing difficult?
Join a clinical research study investigating a potential treatment.
This study could lead to a new potential treatment that not only helps manage symptoms better but also potentially slows the progression of bronchiectasis and provide a better quality of live for those who suffer from this condition.
Description
What to expect
Study details
Ages
18 years or older
Duration
Up to 76 weeks which will include 21 scheduled visits to the clinic
Compensation
Participants will be reimbursed up to $3,150
Eligibility Criteria
You may qualify for this study if you:
- Are 18 years or older
- Have a confirmed diagnosis of bronchiectasis via CT scan.
- Have experienced at least two lung infection requiring antibiotics in the past year OR
- One lung infection and have a score greater than 40 on the St. George's Respiratory Questionnaire (SGRQ).
Other criteria will apply.
Locations
Description
Bronchiectasis is a chronic lung condition that affects the airways. It is a serious and often debilitating condition that makes it harder for people to breathe and fight off lung infections.
Normal function of the lungs is disrupted, leading to a buildup of mucus that is difficult to clear. Over time, this cycle of infection and damage worsens, making the airways even more prone to problems.
Treatment typically includes antibiotics, therapies to clear mucus, and sometimes surgery. However, there are no current treatments that address the underlying inflammation effectively.
The investigational medication in this study is designed to target the proteins involved in lung inflammation, potentially reducing damage and improving breathing.
This study will evaluate how effective the study medicine is at reducing the number of severe lung flare ups, as well as how it affects overall lung function and quality of life.
Register your interest now and find out if participating in this study is right for you. Your privacy is important to us, and all information shared will be kept confidential.
What to expect
Participants will be randomly assigned to receive either the investigational product or a placebo daily for up to 76 weeks. During this time, you will visit the clinic regularly and our professional medical team will monitor your health and lung function. The study will track the number of lung flare-ups and assess lung health through breathing tests and questionnaires.
This advertisement has been reviewed and approved by the Health & Disability Ethics Committee (HDEC).
Apply now
Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.
Momentum Clinical Research NZ is a member of the Global Site Holdings Group. Global Site Holdings Pty Limited ACN 668 977 062 trading as Momentum Clinical Research ABN 51 668 977 062 and our related entities (we, us, our), will use the Personal Information you have provided in the above form to review and respond to your enquiry, to contact you about any future trials or studies you may be eligible for, and otherwise in accordance with our Privacy Policy and as required and authorised by law. We may not be able to provide you with a complete response or a response at all to your enquiry if you do not provide the requested information. Our Privacy Policy also contains further information about how we collect, use, store or disclose your Personal Information, how you may seek access and correction of your Personal Information, and how you may make a complaint about a breach of privacy. If you have questions, please contact us at contact@momentumclinicalresearch.com.